摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

D-Mannit-1-stearat | 22522-17-4

中文名称
——
中文别名
——
英文名称
D-Mannit-1-stearat
英文别名
[(2R,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl] octadecanoate
D-Mannit-1-stearat化学式
CAS
22522-17-4
化学式
C24H48O7
mdl
——
分子量
448.641
InChiKey
KEFRSFBGIAUBNZ-LUGTWXOSSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.4
  • 重原子数:
    31
  • 可旋转键数:
    23
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.96
  • 拓扑面积:
    127
  • 氢给体数:
    5
  • 氢受体数:
    7

文献信息

  • METHODS AND MATERIALS FOR TREATING INFLAMMATORY CONDITIONS
    申请人:Holmdahl Rikard
    公开号:US20080262197A1
    公开(公告)日:2008-10-23
    The invention provides methods and materials for treating inflammatory conditions. Specifically, the invention provides polypeptides, isolated nucleic acids, host cells, and methods that can be used to induce an antibody response in a mammal against an antigen such as C5 or C5a. For example, the methods and materials described herein can be used to reduce the effects of C5a within a mammal by reducing the amount of total and receptor bound C5a in the mammal.
  • [EN] PHARMACEUTICAL FORMULATIONS COMPRISING 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPERAZIN-1 -YL)-2-(1,3-DIMETHYL-1 HPYRAZOL-4-YL)-3H- IMIDAZO[4,5-B]PYRIDINE<br/>[FR] FORMULATIONS PHARMACEUTIQUES COMPRENANT DU 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPÉRAZIN-1-YL)-2-(1,3-DIMÉTHYL-1 HPYRAZOL-4-YL)-3 H-IMIDAZO[4,5-B]PYRIDINE
    申请人:ELLIPSES PHARMA LTD
    公开号:WO2021176214A1
    公开(公告)日:2021-09-10
    The present invention relates to formulations comprising a compound of Formula (1) (6-chloro-7-(4-(4- chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine) which is an inhibitor of Aurora kinase enzyme activity and FMS-like tyrosine kinase 3 (FLT3) activity, and a non-ionic surfactant. The present invention also relates to processes for the preparation of the formulations of the compound, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Aurora kinase and/or FLT3 activity is implicated.
查看更多